Neutralizing Monoclonal Antibody Sars-Cov

SARS-CoV-2 Spike Monoclonal Antibody

A73664
  • EUR 341.00
  • EUR 518.10
  • 50 ul
  • 100 ul

Human IgG antibody Laboratories manufactures the neutralizing monoclonal antibody sars-cov reagents distributed by Genprice. The Neutralizing Monoclonal Antibody Sars-Cov reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Monoclonal. Other Neutralizing products are available in stock. Specificity: Neutralizing Category: Monoclonal Group: Antibody Sars-Cov

SARS-CoV-2 Monoclonal Antibody, N-Ab3

50 µg/50 µl Ask for price

SARS-CoV-2 Monoclonal Antibody, N-Ab3

100 µg/100 µl Ask for price

SARS-CoV-2 Monoclonal Antibody, N-Ab3

1 mg Ask for price

SARS-CoV-2 Monoclonal Antibody, S-Ab401.1

50 µg/50 µl Ask for price

SARS-CoV-2 Monoclonal Antibody, S-Ab401.1

100 µg/100 µl Ask for price

SARS-CoV-2 Monoclonal Antibody, S-Ab401.1

1 mg Ask for price

SARS-CoV/SARS-CoV-2-Nucleocapsid-Antibody,-Rabbit-MAb

2019-nCoV-rabbit-monoclonal-antibody
EUR 416.5
Description: 2019-nCoV rabbit monoclonal antibody

Antibody Sars-Cov information

GENLISA SARS-CoV-2 (Covid-19) Omicron Neutralizing Antibody [S1+S2 Trimer] (B.1.1.529) ELISA

KBVH510 1 x 96 wells
EUR 665.5

Mouse-anti-COVID-19/SARS-CoV-2-Monoclonal-Antibody(Neutralizing)

E40MAV109 N/A
EUR 346.5
Description: N/A

GENLISA SARS-CoV-2 (Covid-19) Delta/DeltaPlus Neutralizing Antibody (B.1.617.2, AY.1,AY.2) ELISA

KBVH430 1 x 96 wells
EUR 665.5

Mouse Monoclonal Anti-HIV-1 gp120 (PND, principal neutralizing domain) IgG

AB-15110 100 ug
EUR 416.4

Mouse monoclonal Anti-MERS Spike protein RBD (MES-RBD) IgG1 (neutralizing)

MERS125-M 100 ul
EUR 578.4

Spike S1 Neutralizing Antibody (WT, B.1.1.7 and B.1.351 Variant) (Clone C-A11) (SARS-CoV-2)

101024 100 µg
EUR 585
Description: This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the B.1.1.7 variant, originally discovered in the U.K, and the B.1.351 variant, originally discovered in South Africa, for both the Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 spike proteins and ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (BPS Bioscience, #78018, #78133, #78152). This antibody not been tested for cross reactivity with other SARS-CoV-2 variants.

Human Monoclonal Anti-Chikungunya virus (CHIKV) E1_E2 protein IgG1 (neutralizing)

CHIKE13-M 100 ul
EUR 578.4

Rabbit monoclonal Anti-MERS Spike protein (S1/RBD/MERS-RBD) IgG (Neutralizing)

MERS122-M 100 ul
EUR 781.2

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV-1), Biotin-labeled

100785-1 50 µg
EUR 355
Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV-1), Biotin-labeled

100785-2 100 µg
EUR 595
Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

SARS-CoV-2 Variants Neutralizing Antibody 6-plex Panel (Flow Cytometry Multiplex Bead Assay)

FCM-N04R 96tests
EUR 1187.7
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide.As the virus spreads globally, the continuous emergence of new mutant strains escalated the challenge on humans.To facilitate the mutant-related research, drug trials and vaccine development, a multiplex serological test for assessing antibody responses to mutant strains is in urgent need.

Spike Trimer Neutralizing Antibody (B.1.617.2, B.1.617.2.1, WT and B.1.1.7 Variants) (Clone hC-A11) (SARS-CoV-2)

101061 100 µg
EUR 475
Description: This antibody is a humanized monoclonal antibody which recognizes SARS-CoV-2 spike RBD and the full-length spike proteins in the native trimeric conformation. This antibody is derived from rabbit monoclonal C-A11 neutralizing antibody (BPS Bioscience, #101024). It cross-reacts with the wildtype as well as the B.1.617.2 (Delta Variant), B.1.617.2.1 (Delta PLUS Variant), B.1.1.7 (Alpha Variant) RBDs and spike protein trimers [See Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Sike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (available for purchase).

Human-anti-SARS-CoV-2-antibody(Neutralizing)

E28F04204 N/A
EUR 1777.78
Description: N/A

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)

SAD-S35 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122)

SCT-M369 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) (SCT-M369), originally from mouse immunized with recombinant SARS-CoV-2 Spike RBD protein, is recombinantly expressed from HEK293 cells.

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180)

SPD-M180 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105).Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

SARS-CoV-2 Omicron Subvariants Neutralizing Antibody 5-plex Panel (Flow Cytometry Multiplex Bead Assay)

FCM-N06R 96tests
EUR 1187.7
Description: Since December 2019, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, COVID-19, has caused a devastating pandemic worldwide. Omicron is a variant of SARS-CoV-2 first detected in November 2021 and is causing the ongoing COVID-19 pandemic. The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. Its recent descendants BA.2.12.1 and BA.4/5 have surged dramatically to become dominant in the United States and South Africa, respectively. BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma from 3-dose vaccination and, most strikingly, from post-vaccination BA.1 infections.